FY2028 Earnings Estimate for CryoPort Issued By KeyCorp

CryoPort, Inc. (NASDAQ:CYRX) – Analysts at KeyCorp issued their FY2028 earnings per share (EPS) estimates for CryoPort in a report issued on Thursday, November 5th. KeyCorp analyst P. Knight expects that the company will post earnings of ($0.26) per share for the year. KeyCorp has an “Overweight” rating and a $20.00 price target on the stock. The consensus estimate for CryoPort’s current full-year earnings is ($0.88) per share.

Other analysts have also issued reports about the stock. BTIG Research increased their price target on shares of CryoPort from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Guggenheim boosted their price objective on shares of CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Weiss Ratings raised shares of CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. Piper Sandler upgraded shares of CryoPort to a “buy” rating in a research note on Tuesday, October 13th. Finally, Robert W. Baird set a $26.00 target price on shares of CryoPort in a research report on Tuesday, October 13th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $21.69.

CryoPort Price Performance

NASDAQ:CYRX opened at $20.10 on Friday. CryoPort has a fifty-two week low of $7.61 and a fifty-two week high of $21.78. The stock’s 50-day moving average is $17.35 and its two-hundred day moving average is $13.65. The stock has a market cap of $1.02 billion, a PE ratio of -20.72 and a beta of 1.89.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). CryoPort had a negative return on equity of 8.28% and a negative net margin of 21.46%. The business had revenue of $50.22 million during the quarter, compared to analysts’ expectations of $48.66 million.

Institutional Trading of CryoPort

A number of institutional investors have recently added to or reduced their stakes in CYRX. Diversified Trust Co lifted its stake in CryoPort by 3.4% in the third quarter. Diversified Trust Co now owns 19,769 shares of the company’s stock valued at $344,000 after acquiring an additional 657 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in shares of CryoPort during the 3rd quarter worth $40,000. State of Wyoming increased its stake in shares of CryoPort by 9.4% during the 1st quarter. State of Wyoming now owns 42,520 shares of the company’s stock worth $352,000 after purchasing an additional 3,638 shares during the last quarter. Headlands Technologies LLC increased its stake in shares of CryoPort by 14.5% during the 2nd quarter. Headlands Technologies LLC now owns 38,742 shares of the company’s stock worth $608,000 after purchasing an additional 4,906 shares during the last quarter. Finally, Quantinno Capital Management LP raised its holdings in shares of CryoPort by 30.7% during the 1st quarter. Quantinno Capital Management LP now owns 43,966 shares of the company’s stock valued at $364,000 after purchasing an additional 10,337 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at CryoPort

In other news, insider Mark Sawicki sold 10,000 shares of CryoPort stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $19.93, for a total transaction of $199,300.00. Following the completion of the sale, the insider directly owned 92,356 shares in the company, valued at $1,840,655.08. The trade was a 9.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel M. Hancock sold 74,379 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $20.21, for a total value of $1,503,199.59. Following the completion of the sale, the director directly owned 69,052 shares of the company’s stock, valued at approximately $1,395,540.92. The trade was a 51.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is owned by company insiders.

About CryoPort

Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company’s services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.